Raymond Moellering, PhD - 2015 Young Investigator Award
“Targeting Oncogenic Transcription with Synthetic Biologics”
Awarded a $75,000 Young Investigator Award
Transcription factors (TFs) regulate cell state by binding specific DNA sequences, thereby recruiting transcriptional machinery that either activate or repress gene expression. Due to the ubiquitous activity of TFs in all aspects of cellular function, aberrant TF activity is widely and unambiguously implicated in human disease. Modulation of TF activity therefore provides opportunities for the treatment of cancer and other forms of human disease, but, paradoxically, this class of proteins has proven resistant to the development of traditional small molecule therapies. Therefore, new classes of molecules capable of blocking the oncogenic TF activity are urgently needed. The research proposed herein will launch a novel class of synthetic inhibitors that are capable of mimicking the functional properties of a validated and so far “undruggable” oncogenic transcription factor, MYC, thus enabling targeted inhibition of MYC signaling in cancer cells dependent upon it for survival.
"Thanks to the hard work, commitment, and compassion of scientists, researchers, and organizations like the Cancer Research Foundation, there is renewed hope for discovering better treatments and eventually a cure for cancer.
I commend all of you for your outstanding contributions to the field of cancer research. For five decades, your commitment to the crusade against cancer has given hope and comfort to people across the nation."
Former President of the United States
May 05, 1997